Proteogenomic Subtypes of Heart Failure: Integrating Molecular Insights for Precision Medicine

Abstract

Heart failure (HF) is a complex clinical syndrome with diverse etiologies and variable therapeutic responses. Recent advances in proteogenomics—integrating proteomic and genomic data—have enabled the identification of distinct HF subtypes with unique molecular signatures. This review summarizes the latest evidence on proteogenomic classification of heart failure, highlighting its implications for diagnosis, risk stratification, and precision therapeutics. We discuss key epidemiological trends, underlying pathophysiology, major risk factors, clinical presentation, and current diagnostic paradigms, followed by treatment approaches informed by recent omics discoveries. The article provides an in-depth analysis of emerging proteogenomic biomarkers, their translational relevance, and the evolving landscape of guideline-based care, aiming to bridge basic science and clinical practice for cardiology professionals.

Introduction

Heart failure is a leading cause of morbidity and mortality worldwide, characterized by the hearts inability to pump sufficient blood to meet metabolic demands. Traditionally, HF has been classified by left ventricular ejection fraction and clinical phenotype, but this approach fails to capture the biological heterogeneity of the syndrome. Proteogenomics, marrying large-scale protein expression data with genomic variation, is revolutionizing our understanding of HF subtypes. This integrative strategy reveals molecular endotypes that may predict clinical trajectories, therapeutic responses, and patient outcomes more accurately than conventional metrics. This article reviews scientific advances in proteogenomic subtyping of HF, focusing on clinical applicability and future directions.

Epidemiology / Disease Burden

Heart failure affects an estimated 64 million people globally, imposing a substantial healthcare burden. Incidence and prevalence rise with age, and HF is associated with high rates of hospitalization, rehospitalization, and mortality. Despite guideline-directed therapies, prognosis remains poor for many patients, underscoring the need for refined subtyping to enable targeted interventions. Recent epidemiological studies leveraging omics data reveal that molecularly defined HF subtypes may differ in prevalence across populations, reflecting genetic, environmental, and socioeconomic influences.

Pathophysiology

HF pathogenesis encompasses a spectrum of molecular derangements—neurohormonal activation, inflammation, metabolic dysregulation, and maladaptive remodeling. Proteogenomic analyses have delineated subgroups characterized by specific protein expression patterns and genetic variants. For example, some HF subtypes exhibit upregulation of fibrotic pathways, while others demonstrate heightened inflammatory signatures or metabolic impairment. These findings suggest that diverse molecular mechanisms drive clinical HF phenotypes, with proteogenomic profiling offering mechanistic insights beyond classical histopathology.

Risk Factors

Major HF risk factors include ischemic heart disease, hypertension, diabetes mellitus, obesity, and genetic predisposition. Proteogenomic studies have identified novel risk loci and protein biomarkers associated with distinct HF subtypes. For instance, variants in genes regulating extracellular matrix turnover, mitochondrial function, and immune response have been linked to specific proteomic profiles and heightened HF susceptibility. Comprehensive risk assessment now increasingly incorporates molecular data to refine patient stratification.

Clinical Features

Symptoms of HF—dyspnea, fatigue, edema—are commonly shared across proteogenomic subtypes. However, emerging evidence indicates that certain molecular subgroups may present with unique clinical trajectories. For example, patients with inflammatory proteogenomic profiles may exhibit more rapid progression or higher rates of arrhythmic events. Subtype-specific symptom clusters and biomarker patterns are being actively investigated, with the potential to inform personalized symptom monitoring and prognostication.

Diagnosis

Diagnosis of HF traditionally relies on clinical examination, imaging modalities (e.g., echocardiography), and natriuretic peptide assays. Proteogenomic advances now enable the detection of subtype-specific biomarkers—such as distinct protein signatures detectable in plasma—that can augment standard diagnostic tools. Integrative diagnostic algorithms incorporating genomic risk scores and proteomic panels are under development, aiming to enhance early detection, differentiation of HF types, and identification of underlying etiologies.

Treatment & Management

Current HF management strategies include pharmacologic therapies (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors), device-based interventions, and lifestyle modification. Proteogenomic subtyping offers the promise of tailoring therapy to molecular disease drivers. For example, patients with elevated inflammatory markers may benefit from targeted anti-inflammatory therapies, while those with metabolic derangement could respond preferentially to agents modulating energy pathways. Molecular subtyping may also identify patients at risk for adverse drug reactions, enabling safer, more effective treatment.

Recent Advances / Emerging Therapies

Recent years have seen rapid progress in the application of mass spectrometry-based proteomics and next-generation sequencing to HF cohorts. These approaches have uncovered novel therapeutic targets, such as circulating proteins involved in fibrosis, inflammation, or energetics. Clinical trials are underway evaluating agents that selectively modulate these pathways in molecularly defined HF subgroups. Additionally, machine learning techniques are being applied to integrate proteogenomic data with electronic health records, refining risk prediction and treatment algorithms. The translation of these advances into routine care is poised to transform HF management.

Guideline Recommendations

International guidelines from societies such as the European Society of Cardiology and the American College of Cardiology increasingly acknowledge the role of biomarkers and omics data in HF assessment. While routine proteogenomic profiling is not yet standard of care, expert consensus supports its use in research settings and selected clinical contexts, such as unexplained or refractory HF. Ongoing updates to professional guidelines are expected as evidence accumulates for the clinical validity and utility of proteogenomic subtyping.

Conclusion

Proteogenomic subtyping represents a paradigm shift in heart failure, offering unprecedented resolution of disease heterogeneity and paving the way for precision medicine. Integration of proteomic and genomic data enhances our understanding of HF mechanisms, risk stratification, and therapeutic targeting. As omics technologies become more accessible, their incorporation into clinical practice is likely to improve outcomes for patients with HF. Continued research, interdisciplinary collaboration, and thoughtful guideline integration will be essential to fully realize the promise of proteogenomics in cardiovascular care.